ERBB2 and breast carcinoma: In PIK3CA-mutated HR+/HER2- breast cancer, targeted degradation and inhibition of mutant p110α with inavolisib combined with CDK4/6 inhibition offers a compelling strategy to block both oncogenic signaling and cell-cycle progression.